Fresenius Medical Care AG & Co. KGaA (ETR:FME) Given a €35.00 Price Target by Credit Suisse Group Analysts

Credit Suisse Group set a €35.00 ($37.63) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) in a research note issued to investors on Tuesday morning, Borsen Zeitung reports.

A number of other research analysts have also recently commented on FME. Deutsche Bank Aktiengesellschaft set a €23.00 ($24.73) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Thursday, March 9th. Barclays set a €32.00 ($34.41) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, February 22nd. Jefferies Financial Group set a €22.00 ($23.66) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, February 21st. JPMorgan Chase & Co. set a €17.10 ($18.39) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Monday, February 20th. Finally, Berenberg Bank set a €46.83 ($50.35) target price on Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, March 8th.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.7 %

FME opened at €37.35 ($40.16) on Tuesday. Fresenius Medical Care AG & Co. KGaA has a one year low of €25.95 ($27.90) and a one year high of €63.60 ($68.39). The stock has a market capitalization of $10.96 billion, a PE ratio of 16.20, a P/E/G ratio of 1.02 and a beta of 0.88. The business’s 50 day moving average price is €34.86 and its 200 day moving average price is €31.82. The company has a debt-to-equity ratio of 85.52, a quick ratio of 0.80 and a current ratio of 1.27.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.